1. Introduction {#sec1-jcm-08-00438}
===============

Prostate cancer (PCa) is the most common type of newly diagnosed malignancy in men \[[@B1-jcm-08-00438]\], and it accounts for nearly 30% of all diagnosed male cancers \[[@B2-jcm-08-00438]\]. Prostate-specific antigen (PSA) measurements are widely used for PCa screening \[[@B3-jcm-08-00438]\], and patients with elevated PSA levels undergo prostate biopsy for PCa diagnosis \[[@B4-jcm-08-00438]\]. The Gleason score (GS) is the most commonly used grading system for PCa. Gleason score at prostate biopsy (bGS) is one of the important parameters in the evaluation, risk stratification, and selection of treatment modality in PCa patients \[[@B5-jcm-08-00438],[@B6-jcm-08-00438]\]. Gleason score was first introduced in 1974 by Donald Gleason and the Veterans Administration Cooperative Urologic Research Group \[[@B7-jcm-08-00438]\]. GS is continuously updated, and it was first revised in 2005 in the International Society of Urological Pathology (ISUP) conference \[[@B8-jcm-08-00438]\]. In the 2014 ISUP meeting, GS was further revised, and a new 5-step Gleason grading system was introduced \[[@B9-jcm-08-00438]\]. Despite these revisions, bGS ≥8 is still considered as high risk \[[@B10-jcm-08-00438]\].

Biopsy and radical prostatectomy (RP) specimens can be discordant due to sampling errors and the multifocal nature of PCa \[[@B11-jcm-08-00438]\]. Several studies have already reported GS discrepancies between biopsy and RP specimens \[[@B12-jcm-08-00438],[@B13-jcm-08-00438]\]. A GS downgrade may also occur in patients with bGS ≥ 8 \[[@B14-jcm-08-00438],[@B15-jcm-08-00438]\]. However, few studies have predicted the discordance in GS between biopsy and RP specimens in patients with bGS ≥ 8. We believe that predicting pathological downgrade (pGS ≤ 7) in patients with high-grade prostate cancer may be beneficial in terms of oncologic outcomes and provide a reliable parameter for defining the appropriate surgical treatment strategy. Therefore, this study aimed to investigate prognostic factors of GS downgrade from biopsy to RP and to investigate oncologic outcomes after RP in patients with bGS ≥ 8.

2. Materials and Methods {#sec2-jcm-08-00438}
========================

2.1. Patients and Study Design {#sec2dot1-jcm-08-00438}
------------------------------

We retrospectively retrieved the clinical and pathological data of 5438 PCa patients who underwent RP at our institution between January 2005 and December 2016. Patients who had undergone androgen deprivation therapy or external beam radiation therapy before RP and those with incomplete pathological or follow-up data were excluded. All patients were diagnosed with PCa via transrectal ultrasound (TRUS)-guided 12-core systematic needle biopsy.

The clinical characteristics of these patients including age, body mass index (BMI), preoperative PSA levels, prostate volume measured via TRUS, clinical stage on multiparametric magnetic resonance imaging (mpMRI), GS following prostate biopsy, and pathologic characteristics of RP specimens were obtained through a review of medical records. The mpMRI images included standardized criteria for Likert scoring of multiparametric sequences using a 3.0-T MRI system (Intera Achieva 3.0-T, Phillips Medical System, Best, The Netherlands) \[[@B16-jcm-08-00438]\]. All pathologic diagnoses were performed by expert pathologists. Biopsy specimens obtained from other hospitals were reviewed by our pathologists. The pathologists also reviewed the missing data in pathological reports of patients included in our study and confirmed that there was no problem. The final identification was performed by the most skilled pathologist to reduce possible errors between pathologists. We assigned GS according to the 2005 ISUP Modified Gleason System \[[@B8-jcm-08-00438]\]. Gleason score at prostate biopsy was based on the core with the highest GS. In case of multifocal disease, GS of the RP specimen was assigned based on the nodule with the highest GS. Tertiary Gleason 5 patterns were assigned if the tertiary component comprised \<5% of the entire tumor \[[@B17-jcm-08-00438]\]. Gleason score downgrade was defined as a downgrade to GS ≤ 7 in the RP specimen from a bGS ≥ 8, which is classified as high-grade.

Finally, the tumor-node-metastasis (TNM) stage was determined according to the 8th edition of the American Joint Committee on Cancer TNM staging system.

2.2. Follow-Up {#sec2dot2-jcm-08-00438}
--------------

Follow-up postoperative PSA test was performed monthly for the first 6 months, every 3 months until the second year, and every 6 months thereafter. Biochemical recurrence (BCR) was defined as any two consecutive increases in serum PSA ≥ 0.2 ng/mL following RP. Biochemical recurrence -free survival was defined as the time from RP to BCR \[[@B18-jcm-08-00438]\]. The follow-up period was calculated from the time of RP to the date of the last known contact with the patient.

2.3. Statistical Analysis {#sec2dot3-jcm-08-00438}
-------------------------

Univariate and multivariate Cox proportional hazards regression analyses were performed to assess the association between baseline parameters and BCR-free survival. In addition, univariate and multivariate logistic regression were performed to identify significant factors of pathologic downgrade. The Kaplan--Meier method with log-rank tests were performed to estimate and compare oncologic outcomes according to variations in GS from RP.

Significant variables from univariate analysis were included in multivariate analysis. All statistical analyses were performed using SPSS Statistics software, version 23.0 (IBM, Armonk, NY, USA), and *p* \< 0.05 was considered statistically significant.

2.4. Ethics Approval and Informed Consent {#sec2dot4-jcm-08-00438}
-----------------------------------------

The current research was approved by the Severance hospital institutional review board (approval number 4-2018-1012). Informed consent from the participants was waived by the institutional review board as the current study satisfied all of the following requirements for the waiver of informed consent: the research involved no more than minimal risk to the participants (retrospective data analysis of previously collected medical records).

3. Results {#sec3-jcm-08-00438}
==========

3.1. Patient and Disease Characteristics {#sec3dot1-jcm-08-00438}
----------------------------------------

Of the 5438 patients identified, 1126 had bGS ≥ 8. After excluding 266 patients who received neoadjuvant therapy, 860 patients were finally included in the analysis. In total, 623 (72.4%) and 237 (27.6%) patients had bGS 8 and bGS ≥ 9, respectively. In the 860 specimens collected following RP, the GS were 6, 7, 8, and ≥ 9 in 19 (2.2%), 313 (36.4%), 219 (25.5%), and 309 (35.9%) specimens, respectively. Among 313 patients in GS 7, 130 (15.1%) had GS (3 + 4) and 183 (21.2%) had GS (4 + 3). Therefore, 332 (38.6%) patients with pGS ≤ 7 were followed after RP for pGS downgrade; the remaining 528 (61.4%) patients had pGS ≥ 8. Median follow-up period after RP was 51 months (interquartile range, 26--78 months). In addition, patients with tertiary G5 patterns in the total RP specimen were observed 15 in GS7 (3 + 4), 23 in GS7 (4 + 3) and 15 in GS8 (4 + 4).

When dividing the two groups (pGS ≤ 7 vs. pGS \> 8) based on pathologic GS, there were significant differences in preoperative PSA, PSA density, clinical stage, and bGS between the two groups. Meanwhile, age, BMI, prostate volume, and follow-up duration did not differ significantly.

After RP, there were statistically significant differences in the pathological features (extracapsular extension (ECE), seminal vesicle invasion (SVI), positive surgical margin (PSM), lymphovascular invasion, and perineural invasion) between the two groups ([Table 1](#jcm-08-00438-t001){ref-type="table"}).

3.2. Preoperative Factors Related to Pathologic Gleason Score (GS) Downgrade (pGS ≤ 7) {#sec3dot2-jcm-08-00438}
--------------------------------------------------------------------------------------

In this study, we used univariate and multivariate logistic regression analyses to identify preoperative predictors of pathologic GS downgrade. Preoperative PSA ≥ 10 ng/mL (odds ratio (OR): 0.606, 95% confidence interval (CI): 0.438--0.840, *p* = 0.003), bGS ≥ 9 (OR: 0.303, 95% CI: 0.213--0.432, *p* \< 0.001), and ≥cT3b on mpMRI (OR: 0.284, 95% CI: 0.176--0.458, *p* \< 0.001) were found to be independent predictors of pathologic GS downgrade at RP in both univariate and multivariate models ([Table 2](#jcm-08-00438-t002){ref-type="table"}). Also, in relate of pathologic downgrade, the area under the curves of the receiver operating characteristic curve was 0.614 (95% CI: 0.575--0.653) in patients with bGS 8, PSA level \< 10 ng/mL, and ≤cT3a.

3.3. Supplementary Analysis of 3-2 (646 Cases) {#sec3dot3-jcm-08-00438}
----------------------------------------------

We analyzed the presence of low-grade PCa core in the biopsy specimens in patients with bGS ≥ 8. In total of 646 cases, we were able to analyze all 12 biopsy cores, including the highest GS. Among the positive biopsy cores, the patients containing Low GS (bGS \< 8) was 356 cases of them. In our result, presence of low GS core in biopsy was statistically significant with pathologic downgrade. (OR 3.967, 95% Cl: 2.698--5.833, *p* \< 0.001). In addition, we analyzed according to the lowest GS in biopsy. The cases including bGS6 were OR 4.926, 95% CI: 3.119--7.779, *p* \< 0.001. The cases including bGS7 (3 + 4) were OR 4.299, 95% CI: 2.566--7.204, *p* \< 0.001. And the cases including bGS7 (4 + 3) were OR 2.259, 95% CI: 0.176--0.458, *p* = 0.006.

3.4. Oncologic Outcomes and Prognostic Factors {#sec3dot4-jcm-08-00438}
----------------------------------------------

During the follow-up period, 502 cases (58.4%) of BCR were noted. Univariate and multivariate Cox regression analyses were performed with each clinical parameter for BCR. In these analyses, preoperative PSA (hazard ratio \[HR\]: 1.005, *p* = 0.003), PSA ≥10 ng/mL (HR: 1.53, *p* \< 0.001), bGS ≥9 (HR: 1.233, *p* = 0.042), pGS (pGS ≤7 vs. pGS 8: HR: 1.699, *p* \< 0.001 and vs. pGS ≥9: HR: 1.765, *p* \< 0.001), SVI (HR: 1.820, *p* \< 0.001), and PSM (HR: 1.819, *p* \< 0.001) were all independent prognostic factors for BCR ([Table 3](#jcm-08-00438-t003){ref-type="table"}).

Analysis according to bGS and pGS using Kaplan--Meier curves was also conduced. In the pGS downgrade group, the Kaplan--Meier curve showed significantly better BCR-free survival than that in the other group (log-rank test, *p* \< 0.001). The 5-year BCR-free survival rates was higher in the pGS downgrade group than that in the other group (50.9% vs. 23.8%). Also, patients with bGS 8, PSA \< 10 ng/mL, and ≤ cT3a showed significantly better 5-year BCR-free survival than the other patients (55.1% vs. 23.4%, *p* \< 0.001; [Figure 1](#jcm-08-00438-f001){ref-type="fig"} and [Figure 2](#jcm-08-00438-f002){ref-type="fig"}).

The patients were then divided into four groups as follows for further analysis: group 1 comprised patients with bGS 8 and pGS \< 7; group 2, patients with bGS ≥ 9 and pGS \< 7; group 3, patients with bGS ≥ 9 and pGS ≥ 8; and group 4, patients with bGS ≥ 9 and pGS ≥ 8. The 5-year BCR-free survival rates for groups 1, 2, 3, and 4 were 52.9%, 40.7%, 27.2%, and 16.9%, respectively. The hazard ratios of groups 2, 3, and 4 compared to group 1 were 2.109 (*p* = 0.146), 38.643 (*p* \< 0.001), and 96.262 (*p* \< 0.001), respectively. The BCR-free survival curves of the four groups are shown in [Figure 3](#jcm-08-00438-f003){ref-type="fig"}.

4. Discussion {#sec4-jcm-08-00438}
=============

Since the introduction of the Gleason Grading System \[[@B7-jcm-08-00438]\], bGS 8 or higher has been consistently classified as high risk and as a predictor of poor oncologic outcome. Patients with bGS 8 are classified to have high-grade prostate cancer (poorly differentiated prostate cancer). Since the 2005 update in the Gleason grading system \[[@B8-jcm-08-00438]\], the correlation between bGS and RP GS has improved \[[@B19-jcm-08-00438],[@B20-jcm-08-00438],[@B21-jcm-08-00438]\]. Major changes in the Gleason system have also been made during the 2014 ISUP \[[@B9-jcm-08-00438]\], and this further improves the association between bGS and pGS \[[@B22-jcm-08-00438]\]. However, some cases of discordant bGS and pGS are still reported. Among patients with PCa, those with GS \> 8, PSA \> 20 ng/mL, or cT3a are considered to be high risk. Although RP is a treatment option in these patients, combined EBRTx and ADT are proposed as the first choice of treatment in the National Comprehensive Cancer Network (NCCN) guideline \[[@B10-jcm-08-00438]\]. The European Association of Urology (EAU) guideline also recommends RP for selected patients \[[@B4-jcm-08-00438]\], and both the EAU and NCCN guidelines recommend RP in select high-risk patients. Therefore, in this study, we investigated the favorable indicators for surgical treatment in patients with high-risk PCa.

pGS downgrade is a well-known favorable prognostic factor, and Donohue et al. \[[@B14-jcm-08-00438]\] reported that patients with high bGS who have pGS downgrade have good prognosis. In their study, cT1c and bGS 8 were identified to be predictors of pGS downgrade, which is similar to our results. However, there were differences about the influence of PSA and clinical stage between the study of Donohue et al. and our study. In our study, PSA was set as a criterion for easy patient and used a PSA value of 10 ng/mL as cut-off for low-risk malignancy based on the current standard \[[@B10-jcm-08-00438]\]. Thus, PSA \<10 ng/mL was evaluated as a predictor for downgrade in patients with high-grade PCa on biopsy findings. In addition, recent developments in mpMRI have improved the image evaluation techniques for ECE and SVI \[[@B23-jcm-08-00438],[@B24-jcm-08-00438]\]. The clinical stage was evaluated using 3T MRI, which enabled us to distinguish between T3a and T3b. Thus, the probability of discordance (i.e., pathologic downgrade) in patients with T3b or higher was minimized. In addition, we found that bGS8, PSA \< 10 ng/mL, and ≤ cT3a were significantly correlated with BCR in patients with high bGS. These factors were also predictors of pathologic downgrade. The Kaplan--Meier curves of the patients with pathologic downgrade and those with bGS8, PSA \< 10 ng/mL, and ≤ cT3a were similar in this study.

Collectively, these results indicate that patients with high-grade PCa who have PSA \< 10 ng/mL, bGS 8, and ≤ cT3a may have favorable oncological outcomes via RP. This information would be valuable in providing an indication for surgical treatment in patients with high-grade PCa. In addition, we believe that bGS remains a crucial factor for determining the appropriate treatment and follow-up strategy for high-grade PCa.

The oncologic outcome has been reported to differ according to bGS among those with similar pGS \[[@B11-jcm-08-00438],[@B22-jcm-08-00438]\]. In our study, we also found that BCR-free survival decreased as bGS increased among those with similar pGS. This suggests that although pGS downgrades may be observed in patients with high-grade PCa on biopsy, these patients require a more aggressive management after RP than those with low-grade PCa.

Our study has several limitations. First, this was a retrospective review of data from patients treated at a single institution. Thus, our results are subject to selection bias, limiting generalizability. Therefore, multi-center, prospective studies are needed. Second, mpMRI findings have been recently read based on the Prostate Imaging Reporting and Data System (PI-RADS) \[[@B25-jcm-08-00438],[@B26-jcm-08-00438]\]. However, until 2009 we did not include diffusion-weighted imaging and the apparent-diffusion coefficient in the mpMRI protocol. Therefore, it was difficult to perform a complete PI-RADS scoring. Recently, PI-RADS scoring has been reported to be associated with GS \[[@B27-jcm-08-00438],[@B28-jcm-08-00438]\], and this requires further analysis. Third, given the referral nature of our tertiary center, many men underwent biopsy at outside hospitals. While all biopsy slides were re-examined by a single experienced group of urological pathologists at our institute, biopsy data were lacking in some cases, such as the number of positive cores, percentage of cancer per core, and perineural invasion. In our study, the presence of low GS (bGS \<8) core in positive biopsy cores and pathologic downgrade were statistically significant. Unfortunately, as mentioned earlier, biopsy data were lacking in some cases. Therefore, it was difficult to analysis the average cancer portion for all biopsy cores. We think that this analysis may be a good study to reduce the discordance of biopsy and final GS. However, as a tertiary center, we were able to accommodate many patients with high-grade PCa. Therefore, a large number of patients were included in this study. In addition, in the era of mpMRI, the index core via mpMRI fusion biopsy could be one factor that could reduce GS discrepancies between biopsy and RP specimen. Unfortunately, this was not included in our current study. Therefore, we believe that further research on this content is necessary.

Despite these limitations, our study is still valuable in that it demonstrates that bGS 8, PSA \< 10 ng/mL, and \< cT3b were independent predictors of downgrading GS after RP in patients with high-grade PCa. In addition, these factors were determined to be predictors of favorable oncological outcome in these patients. Our findings provide a guide for predicting disease prognosis and subsequent treatment planning in patients with high-grade PCa.

5. Conclusions {#sec5-jcm-08-00438}
==============

Among patients with high-risk PCa (i.e., those with bGS ≥ 8), those with bGS 8, PSA \< 10 ng/mL, and without SVI on mpMRI may have pGS downgrade and favorable oncologic outcomes. These patients have fewer adverse pathologic features and can thus benefit from RP in terms of oncologic prognosis. Therefore, we suggest active treatment such as RP in these patients.
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jcm-08-00438-t001_Table 1

###### 

Baseline patient characteristics.

  --------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                              Total   No_Downgrade   Downgrade   *P* value                             
  ----------------------------------------------------- ------- -------------- ----------- -------------- ------- -------------- -------------
  Age, year                                             67      62--71         67          62--71         66      62--70         0.578

  BMI, kg/m^2^                                          24.09   22.38--25.97   24.05       22.32--25.90   24.22   22.50--26.00   0.608

  PSA level, ng/mL                                      10.59   6.58--19.39    12.03       7.09--22.72    8.60    5.99--14.74    \<0.001

  PSA group, ng/mL                                      N       \%             N           \%             N       \%             \<0.001

  \<10                                                  445     51.7           236         44.7           209     63.0           

  ≥10                                                   415     48.3           292         55.3           123     37.0           

  PSA density, ng/mL^2^                                 0.33    0.20--0.62     0.38        0.22--0.75     0.28    0.18--0.50     \<0.001

  Prostate volume, mL                                   32.0    26.0--40.5     32.6        26.0--40.9     31.1    25.8--40.0     0.367

  Clinical stage according to MRI                       N       \%             N           \%             N       \%             \<0.001

  cT2                                                   402     46.7           213         40.3           35      56.9           

  cT3a                                                  292     34.0           176         33.3           116     34.9           

  ≥cT3b                                                 166     19.3           139         26.3           27      8.1            

  Gleason score according to Biopsy                     N       \%             N           \%             N       \%             \<0.001

  8                                                     623     72.4           339         64.2           284     85.5           

  ≥9                                                    237     27.6           189         35.8           48      14.5           

  FU duration after RP, months                          51      26--78         44          25--71         59      32--83         0.317

  **Pathologic Features after Radical Prostatectomy**                                                                            

  **Gleason Score according**\                          **N**   **%**          **N**       **%**          **N**   **%**          
  **to Radical Prostatectomy**                                                                                                   

  6                                                     19      2.2            \-                         19      5.7            

  7 (3 + 4)                                             130     15.1           \-                         130     39.2           

  7 (4 + 3)                                             183     21.2           \-                         183     55.1           

  8                                                     219     25.5           219         41.5           \-                     

  ≥9                                                    309     35.9           309         58.6           \-                     

  **Pathologic T Stage according**\                     **N**   **%**          **N**       **%**          **N**   **%**          **\<0.001**
  **to Radical Prostatectomy**                                                                                                   

  T2                                                    260     30.2           118         22.3           142     42.8           

  T3a                                                   348     40.5           208         39.4           140     42.2           

  ≥T3b                                                  252     29.3           202         38.3           50      15.1           

  ECE                                                   570     66.7           394         74.6           180     54.2           \<0.001

  SVI                                                   214     24.9           164         31.1           50      15.1           \<0.001

  PSM                                                   452     52.6           300         56.8           152     45.8           0.002

  LVI                                                   11      12.7           84          15.9           25      7.5            \<0.001

  PNI                                                   629     73.1           405         76.7           224     67.5           0.003

  HGPIN                                                 371     43.1           204         38.6           167     50.3           0.001

  BCR                                                   502     58.4           360         68.2           142     42.8           \<0.001
  --------------------------------------------------------------------------------------------------------------------------------------------

IQR, interquartile range; BMI, body mass index; PSA, prostate-specific antigen; MRI, magnetic resonance imaging; RP, radical prostatectomy; ECE, extracapsular extension; SVI, seminal vesicle invasion; PSM, positive surgical margin; LVI, lymphovascular invasion; PNI, perineural invasion; HGPIN, high-grade prostatic intraepithelial neoplasia; BCR, biochemical recurrence.

jcm-08-00438-t002_Table 2

###### 

Univariate and multivariate analyses of factors associated with pathologic Gleason score downgrade in patients with biopsy Gleason scores 8--10.

  Variable                          Univariate             Multivariate                          
  --------------------------------- ---------------------- -------------- ---------------------- ---------
  Age, year                         0.995 (0.975--1.015)   0.592                                 
  BMI, kg/m^2^                      1.013 (0.964--1.064)   0.607                                 
  Prostate volume, mL               0.996 (0.986--1.005)   0.367                                 
  PSA level, ng/mL                                                                               
  \<10                              1 (Ref)                               1 (Ref)                
  ≥10                               0.476 (0.359--0.630)   \<0.001        0.606 (0.438--0.840)   0.003
  PSA density                       0.679 (0.540--0.854)   0.001          0.973 (0.799--1.185)   0.783
  Gleason score                                                                                  
  8                                 1 (Ref)                               1 (Ref)                
  ≥9                                0.303 (0.213--0.432)   \<0.001        0.342 (0.238--0.493)   \<0.001
  Clinical stage according to MRI                                                                
  cT2                               1 (Ref)                               1 (Ref)                
  cT3a                              0.743 (0.547--1.008)   0.056          0.816 (0.592--1.123)   0.211
  ≥cT3b                             0.219 (0.139--0.346)   \<0.001        0.284 (0.176--0.458)   \<0.001

OR, odds ratio; CI, confidence interval; Ref, reference value; BMI, body mass index; PSA, prostate-specific antigen; MRI, magnetic resonance imaging.

jcm-08-00438-t003_Table 3

###### 

Univariate and multivariate analyses of factors associated with biochemical recurrence.

  Variable                         Univariate             Multivariate                          
  -------------------------------- ---------------------- -------------- ---------------------- ---------
  Age, year                        1.005 (0.992--1.018)   0.469                                 
  BMI, kg/m^2^                     1.014 (0.982--1.046)   0.399                                 
  Prostate volume, ml              1.003 (0.997--1.008)   0.363                                 
  PSA, ng/ml                       1.006 (1.005--1.008)   \<0.001        1.005 (1.002--1.009)   0.003
  \<10                             1 (Ref)                               1 (Ref)                
  ≥10                              2.341 (1.956--2.803)   \<0.001        1.539 (1.260--1.880)   \<0.001
  PSA density, ng/mL^2^            1.186 (1.127--1.249)   \<0.001        0.888 (0.780--1.011)   0.073
  Biopsy Gleason score (bGS)                                                                    
  8                                1 (Ref)                               1 (Ref)                
  ≥9                               1.784 (1.485--2.143)   \<0.001        1.233 (1.008--1.508)   0.042
  Pathologic Gleason score (pGS)                                                                
  ≤7 (pGS_downgrade)               1 (Ref)                               1 (Ref)                
  8                                1.735 (1.366--2.204)   \<0.001        1.699 (1.328--2.175)   \<0.001
  ≥9                               2.810 (2.272--3.474)   \<0.001        1.765 (1.396--2.231)   \<0.001
  Pathologic T stage                                                                            
  ≤T2                              1 (Ref)                               1 (Ref)                
  ≥T3                              5.044 (3.910--6.508)   \<0.001        1.409 (0.788--2.520)   0.247
  ECE                                                                                           
  No                               1 (Ref)                               1 (Ref)                
  Yes                              2.641 (2.122--3.286)   \<0.001        1.016 (0.594--1.737)   0.955
  SVI                                                                                           
  No                               1 (Ref)                               1 (Ref)                
  Yes                              3.139 (2.598--3.792)   \<0.001        1.820 (1.473--2.249)   \<0.001
  PSM                                                                                           
  No                               1 (Ref)                               1 (Ref)                
  Yes                              2.775 (2.298--3.351)   \<0.001        1.819 (1.476--2.242)   \<0.001
  LVI                                                                                           
  No                               1 (Ref)                               1 (Ref)                
  Yes                              2.069 (1.639--2.612)   \<0.001        1.260 (0.987--1.608)   0.063
  PNI                                                                                           
  No                               1 (Ref)                               1 (Ref)                
  Yes                              2.013 (1.612--2.512)   \<0.001        1.244 (0.979--1.580)   0.074
  HGPIN                                                                                         
  No                               1 (Ref)                                                      
  Yes                              0.870 (0.728--1.040)   0.126                                 

HR, hazard ratio; CI, confidence interval; Ref, reference value; BMI, body mass index; PSA, prostate-specific antigen; ECE, extracapsular extension; SVI, seminal vesicle invasion; PSM, positive surgical margins; LVI, lymphovascular invasion; PNI, perineural invasion; HGPIN, high-grade prostatic intraepithelial neoplasia; BCR, biochemical recurrence.
